Solventum Corporation Common Stock (SOLV)
Stock · NYSE · Health Care
$85.81as of 10/16/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
SOLV Signal Track Record
How signals performed across all stocks →What SOLV's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 11 | -1.1% | 45% | July 16, 2026 |
| 200-Day Moving Average Touch | 11 | +3.1% | 73% | July 8, 2026 |
| Volume Spike | 10 | +4.1% | 70% | September 18, 2026 |
| Bollinger Band Breakdown | 5 | +1.3% | 60% | October 7, 2026 |
| Any 20-session window (baseline) | +0.7% | 54% |
Computed by MarketWall from daily closing prices since January 10, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SOLV
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 20,584
Fundamentals
- 1-day range
- $88.36$89.89
- Market cap
- $14.37B
- P/E (trailing)
- 10.62
- P/E (forward)
- 12.38
- EPS (trailing)
- $8.19
- Dividend yield
- —
- Beta
- 0.73
- Avg. volume
- 1.06M
How Solventum Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
Solventum Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- SOLVSolventum Corporation Common Stock$85.81▼ 2.33%Market cap $14.37BP/E 10.62$62.38$94.16
- BAXBaxter International Inc. Common Stock$25.28▼ 1.86%Market cap $13.96BP/E —$15.73$30
- GMEDGlobus Medical Inc. Class A Common Stock$76.71▼ 2.70%Market cap $11.01BP/E 19.14$56.96$101.4
- GKOSGlaukos Corporation Common Stock$164.84▼ 0.46%Market cap $10.09BP/E —$73.16$191.62
- PODDInsulet Corporation Common Stock$141.1▲ 1.68%Market cap $9.65BP/E 25.40$126.4$354.88
- TFXTeleflex Incorporated Common Stock$130.43▲ 1.72%Market cap $6.15BP/E —$100.18$145
- STVNStevanato Group S.p.A. Ordinary Shares$18.9▼ 1.82%Market cap $6.14BP/E 34.82$12.89$27.99
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SOLV Solventum Corporation Common Stock | $14.37B | 10.62 | $85.81 | ▼ 2.33% | $62.38$94.16 |
| BAX Baxter International Inc. Common Stock | $13.96B | — | $25.28 | ▼ 1.86% | $15.73$30 |
| GMED Globus Medical Inc. Class A Common Stock | $11.01B | 19.14 | $76.71 | ▼ 2.70% | $56.96$101.4 |
| GKOS Glaukos Corporation Common Stock | $10.09B | — | $164.84 | ▼ 0.46% | $73.16$191.62 |
| PODD Insulet Corporation Common Stock | $9.65B | 25.40 | $141.1 | ▲ 1.68% | $126.4$354.88 |
| TFX Teleflex Incorporated Common Stock | $6.15B | — | $130.43 | ▲ 1.72% | $100.18$145 |
| STVN Stevanato Group S.p.A. Ordinary Shares | $6.14B | 34.82 | $18.9 | ▼ 1.82% | $12.89$27.99 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- How Is Solventum's Stock Performance Compared to Other Healthcare StocksYahoo · 9/25/2026
- Ostomy Dressing Market Forecasts Growth from $3.80B (2026) to $4.73B by 2031, Profiling Coloplast, ConvaTec, Hollister, B. Braun & Salts HealthcareYahoo · 9/24/2026
- Temperature Management Systems Market Forecasts Growth from $3.56B (2026) to $4.58B by 2031, Profiling 3M, Asahi-Kasei, GE Healthcare, Dragerwerk & MedtronicYahoo · 9/24/2026
- Solventum (NYSE:SOLV) Forms Tight Breakout Setup as Technical Strength BuildsChartMill · 9/23/2026
- Solventum: Divestiture Unlocking Upside In A Spinoff Revaluation PlaySeekingAlpha · 9/18/2026
- Here's Why You Should Hold Solventum Stock in Your Portfolio for NowYahoo · 9/17/2026
- What Solventum (SOLV)'s Earnings Beat and Surgical AI Push Means For ShareholdersYahoo · 9/17/2026
- Q2 Surgical Equipment & Consumables - Diversified Earnings: Solventum (NYSE:SOLV) ImpressesYahoo · 9/16/2026
Insider Activity
Insider Actions →- Bryan C. Hanson · September 1, 2026 · Option Exercise67.3K
- Bryan C. Hanson · September 1, 2026 · Tax Withholding26.5K @ $90.95
- Zieselman Neil Craig · August 17, 2026 · Grant6.9K
- Shirley Ann Edwards · May 15, 2026 · Grant3.3K
- Elizabeth Mily · May 15, 2026 · Grant3.3K
- Darryl L. Wilson · May 15, 2026 · Grant3.3K
- Susan D. DeVore · May 15, 2026 · Grant3.3K
- Carlos Alban · May 15, 2026 · Grant3.3K
- Amy McBride Wendell · May 15, 2026 · Grant3.3K
- Bernard A. Harris Jr. · May 15, 2026 · Grant3.3K
- Glenn A. Eisenberg · May 15, 2026 · Grant3.3K
- John H. Weiland · May 15, 2026 · Grant3.3K
- Karen J. May · May 15, 2026 · Grant3.3K
- Carrie Smith Cox · May 15, 2026 · Grant4.8K
- Wayde D. McMillan · May 13, 2026 · Option Exercise9.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 120.62M
- Total value held
- $7.70B
- Institutional holders
- 860
- Unknown15.73M
- Unknown10.48M
- Unknown9.60M
- Unknown8.24M
- Unknown6.41M
- Unknown6.33M
- Unknown4.75M
- Unknown3.91M
- Unknown3.79M
- Unknown2.42M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Solventum Featured in Yahoo’s Overrated and Profitable Stock Lists
Yahoo highlighted Solventum in two recent articles. In one piece it was listed among stocks that may be overvalued, while the other article named it a profitable long‑term option. The coverage may influence how investors view the company’s valuation and growth prospects. The stock remains near the middle of its 52‑week range.
Solventum Featured in Yahoo’s Overrated and Profitable Stock Lists. Yahoo highlighted Solventum in two recent articles. In one piece it was listed among stocks that may be overvalued, while the other article named it a profitable long‑term option. The coverage may influence how investors view the company’s valuation and growth prospects. The stock remains near the middle of its 52‑week range.